User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Haemophilia care in Europe: the ESCHQoL study.

Primary tabs

Schramm, Wolfgang Gringeri, Alessandro Ljung, Rolf Berger, Karin Crispin, Alexander Hermans, Cédric [UCL]

The aim of this study was to determine the clinical conditions of patients with haemophilia within Europe as recommended by the European Commission. In this multicentre, cross-sectional, ambispective study, conducted within 21 European countries patients' clinical data were collected, amongst others haemophilia type, severity, treatment pattern, use of factor products, bleeding, orthopaedic joint scores and infections. A total of 1400 patients, 84.3% with haemophilia A and 15.7% with haemophilia B were enrolled by 42 centres between 2004 and 2006. Thereof, 417 were children (30.0%) and 983 were adults (70.0%). About 70% of patients had severe factor deficiency (<1%). More than half of the adults were carriers of chronic infections (12.6% HIV, 55.8% HCV), compared to only 3.8% children (no HIV, 2.9% HCV). Patients were grouped according to per capita amount of clotting factor used in patients' region of residence in 2005: region 1: >5 IU; region 2: 2-5 IU; region 3: <2 IU. Paediatric and adult patients in region 3 had median numbers of three and eight joint bleeds, respectively, with worse joint scores compared to region 1 with zero and one bleed. Prophylactic therapy was used in only 31.3% children and 8.9% adults with severe haemophilia in region 3 compared to 93.7% and 54.1%, respectively, in region 1. Statistical analysis revealed that residence in areas with low factor consumption/availability is the most prominent risk factor for joint disease. Access of European patients with haemophilia to optimal care with safe factor VIII concentrates is limited and depends on the region of residence.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2012
Language Anglais
Journal information "Haemophilia" - Vol. 18, no. 5, p. 729-737 (2012)
Peer reviewed yes
Publisher Blackwell Science ((United Kingdom) Oxford)
issn 1351-8216
e-issn 1365-2516
Publication status Publié
Affiliations UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
UCL - (SLuc) Service d'hématologie
Links
  1. COLVIN B. T., ASTERMARK J., FISCHER K., GRINGERI A., LASSILA R., SCHRAMM W., THOMAS A., INGERSLEV J., , European principles of haemophilia care, 10.1111/j.1365-2516.2007.01625.x
  2. Gross domestic product (GDP) per capita http://wwwstatsoecdorg
  3. MEMO/08/625, Brussels (2008)
  4. GRINGERI A., LUNDIN B., VON MACKENSEN S., MANTOVANI L., MANNUCCI P. M., , A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) : Prophylaxis in hemophilia A, 10.1111/j.1538-7836.2011.04214.x
  5. Manco-Johnson Marilyn J., Abshire Thomas C., Shapiro Amy D., Riske Brenda, Hacker Michele R., Kilcoyne Ray, Ingram J. David, Manco-Johnson Michael L., Funk Sharon, Jacobson Linda, Valentino Leonard A., Hoots W. Keith, Buchanan George R., DiMichele Donna, Recht Michael, Brown Deborah, Leissinger Cindy, Bleak Shirley, Cohen Alan, Mathew Prasad, Matsunaga Alison, Medeiros Desiree, Nugent Diane, Thomas Gregory A., Thompson Alexis A., McRedmond Kevin, Soucie J. Michael, Austin Harlan, Evatt Bruce L., Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, 10.1056/nejmoa067659
  6. SOUCIE J. M., WANG C., SIDDIQI A., KULKARNI R., RECHT M., KONKLE B. A., , The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A : BODY ADIPOSITY AND HAEMOPHILIA ON JOINT MOBILITY, 10.1111/j.1365-2516.2010.02400.x
  7. STONEBRAKER J. S., BROOKER M., AMAND R. E., FARRUGIA A., SRIVASTAVA A., A study of reported factor VIII use around the world, 10.1111/j.1365-2516.2009.02131.x
  8. Gilbert, Semin Hematol, 30, 3 (1993)
  9. Feldman Brian M., Funk Sharon M., Bergstrom Britt-Marie, Zourikian Nichan, Hilliard Pamela, van der Net Janjaap, Engelbert Raoul, Petrini Pia, van den Berg H. Marijke, Manco-Johnson Marilyn J., Rivard Georges E., Abad Audrey, Blanchette Victor S., Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score, 10.1002/acr.20353
  10. BLANCHETTE V. S., Prophylaxis in the haemophilia population : PROPHYLAXIS IN THE HAEMOPHILIA POPULATION, 10.1111/j.1365-2516.2010.02318.x
  11. Schramm, Optimal Clinical Use of Blood Components (2009)
  12. Schramm W Blood safety in the European Community: an initiative for optimal use. Conclusions and Recommendations, Discussion papers, Syllabus Wildbad Kreuth, Germany 1999
  13. O’MAHONY B., NOONE D., GIANGRANDE P. L. F., PRIHODOVA L., Haemophilia care in Europe: a survey of 19 countries : HAEMOPHILIA CARE IN EUROPE, 10.1111/j.1365-2516.2010.02362.x
  14. Lee C. A., Kessler C. M., Varon D., Martinowitz U., Heim M., SZUCS T. D., ÖFFNER A., KRONER B., GIANGRANDE P., BERNTORP E., SCHRAMM W., , Resource utilisation in haemophiliacs treated in Europe: Results from the European Study on Socioeconomic Aspects of Haemophilia Care, 10.1046/j.1365-2516.1998.440498.x
  15. SCHRAMM W., ROYAL S., KRONER B., BERNTORP E., GIANGRANDE P., LUDLAM C., GRINGERI A., BERGER K., SZUCS T., , Clinical outcomes and resource utilization associated with haemophilia care in Europe, 10.1046/j.1365-2516.2002.00580.x
  16. ROYAL S., SCHRAMM W., BERNTORP E., GIANGRANDE P., GRINGERI A., LUDLAM C., KRONER B., SZUCS T., , Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients, 10.1046/j.1365-2516.2002.00581.x
  17. Miners, Sabin, Tolley, Jenkinson, Kind, Lee, Assessing health-related quality-of-life in individuals with haemophilia, 10.1046/j.1365-2516.1999.00347.x
  18. Darby S. C., Kan S. W., Spooner R. J., Giangrande P. L. F., Hill F. G. H., Hay C. R. M., Lee C. A., Ludlam C. A., Williams M., , Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV, 10.1182/blood-2006-10-050435
  19. Plug I., Thirty years of hemophilia treatment in the Netherlands, 1972-2001, 10.1182/blood-2004-05-2008
  20. ROSENDAAL F. R., SMIT C., VAREKAMP I., BRÖCKERVRIENDS A. H. J. T., DIJCK H., SUURMEIJER T. P. B. M., VANDENBROUCKE J. P., BRIËT E., Modern haemophilia treatment: medical improvements and quality of life, 10.1111/j.1365-2796.1990.tb00291.x
  21. DEN UIJL I. E. M., FISCHER K., VAN DER BOM J. G., GROBBEE D. E., ROSENDAAL F. R., PLUG I., Clinical outcome of moderate haemophilia compared with severe and mild haemophilia, 10.1111/j.1365-2516.2008.01837.x
  22. AZNAR J. A., LUCÍA F., ABAD-FRANCH L., JIMÉNEZ-YUSTE V., PÉREZ R., BATLLE J., BALDA I., PARRA R., CORTINA V. R., Haemophilia in Spain, 10.1111/j.1365-2516.2009.02001.x
  23. Gringeri A., Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group, 10.1182/blood-2003-03-0941
  24. Molho, Rolland, Lebrun, Dirat, Courpied, Croughs, Duprat, Sultan, , Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France, 10.1046/j.1365-2516.2000.00358.x
  25. Wenzel, Haemostasis, 28, 106 (1998)
  26. HARTL H. K., REITTER S., EIDHER U., RAMSCHAK H., AY C., PABINGER I., The impact of severe haemophilia on the social status and quality of life among Austrian haemophiliacs, 10.1111/j.1365-2516.2008.01684.x
  27. World, Federation, of, Hemophilia Guidelines for the Management of Hemophilia http://wwwwfhorg 2005
Bibliographic reference Schramm, Wolfgang ; Gringeri, Alessandro ; Ljung, Rolf ; Berger, Karin ; Crispin, Alexander ; et. al. Haemophilia care in Europe: the ESCHQoL study.. In: Haemophilia, Vol. 18, no. 5, p. 729-737 (2012)
Permanent URL http://hdl.handle.net/2078/125221